Grufity logoGrufity logo

CERT

17.72USD+0.25(+1.43%)Market Closed

Certara, Inc.

Market Summary

USD17.72+0.25Market Closed
1.43%

CERT Alerts

CERT Stock Price

RSI Chart

Valuation

Market Cap

1.9B

Price/Earnings

-195.63

Price/Sales

6.14

Price/Cashflow

26.05

MarketCap/EBT

644.45

Price/Sales

Profitability

Operating Margin

59.81%

EBT Margin

0.95%

Return on Equity

-0.94%

Return on Assets

-0.66%

Fundamentals

Revenue

Revenue (TTM)

324.4M

Revenue Y/Y

14.55%

Revenue Q/Q

2.34%

Earnings

Earnings (TTM)

-4.1M

Earnings Y/Y

323.38%

Earnings Q/Q

768.25%

Price Action

52 Week Range

29.99
(Low)(High)

Last 7 days

12.4%

Last 30 days

66.4%

Last 90 days

14.8%

Trailing 12 Months

-32.1%

Financial Health

Current Ratio

3.51

Debt/Equity

0.28

Debt/Cashflow

0.25

Investor Care

Buy Backs (1Y)

0.00%

Diluted EPS (TTM)

-0.04

Financials for Certara

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue3.4%324314301286275
Operating Expenses-2.8%170175168161202
  S&GA Expenses5.2%2625232024
  R&D Expenses6.8%2826232024
Earnings Before Taxes397.9%153-1.21-3.37-63.14
Net Income57.9%-4.14-9.84-12.11-13.27-58.01
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets0.5%1,5091,5021,5071,5121,415
  Current Assets6.7%305286275275505
    Cash Equivalents8.1%211195184186417
  Net PPE-5.1%33333
  Goodwill-0.6%697701705703523
Liabilities0.2%454453459470443
  Current Liabilities-6.1%7782829270
  Long Term Debt-0.1%293294294295295
    LT Debt, Current0%33333
    LT Debt, Non Current-0.2%290291291292292
Shareholder's Equity0.6%1,0541,0481,0481,042971
  Retained Earnings5.3%-70.05-73.98-73.39-75.60-65.90
  Additional Paid-In Capital0.6%1,1441,1371,1271,1201,039
Shares Outstanding-0.1%160160160160157
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations5.4%7874656052
  Share Based Compensation-4.0%3234322928
Cashflow From Investing-0.3%-264.56-263.84-275.14-269.92-22.00
Cashflow From Financing-108.1%-10.04124123123359

Risks

What is the probability of a big loss on CERT?

88.5%


Probability that Certara stock will be more than 20% underwater in next one year

88.5%


Probability that Certara stock will be more than 30% underwater in next one year.

46.1%


Probability that Certara stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CERT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Certara was unfortunately bought at previous high price.

Returns

Cumulative Returns on CERT

Which funds bought or sold CERT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-1,173,000
1,800,000
-%
2022-11-21
FourThought Financial, LLC
-
-
-22,000
35,000
-%
2022-11-17
M&T Bank Corp
-
-
-153,000
683,000
-%
2022-11-16
GLENMEDE TRUST CO NA
ADDED
66.27
267,000
9,510,000
0.06%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-198,000
-
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
NEW
-
653,164
653,164
-%
2022-11-15
Alpha Paradigm Partners, LLC
NEW
-
1,866,000
1,866,000
0.81%
2022-11-15
ALLIANCEBERNSTEIN L.P.
REDUCED
-98.63
-66,961,000
574,000
-%
2022-11-15
Almanack Investment Partners, LLC.
NEW
-
1,000
1,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
ADDED
9.95
-5,000
11,000
-%

1–10 of 47

Latest Funds Activity

Are funds buying CERT calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own CERT

Certara News

ETF Daily News

AlphaCrest Capital Management LLC Takes $239000 Position in Certara, Inc. (NASDAQ:CERT).24 hours ago

Zacks Investment Research

CERT Fair Value

Recent SEC filings of Certara

View All Filings
Date Filed Form Type Document
Nov 23, 2022
4
Insider Trading
Nov 16, 2022
4
Insider Trading
Nov 15, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 07, 2022
10-Q
Quarterly Report
Nov 07, 2022
8-K
Current Report
Nov 07, 2022
8-K
Current Report
Nov 02, 2022
4
Insider Trading
Oct 06, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading

Latest Insider Trading transactions for CERT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-22
Pedersen Leif E
SOLD
-796,518
15.55
-51,223
PRESIDENT, SOFTWARE
2022-11-15
SLAINE MASON P
SOLD
-3,827,000
15.57
-245,793
-
2022-11-14
WALSH MATTHEW M
SOLD
-177,750
14.74
-12,059
-
2022-11-14
SLAINE MASON P
SOLD
-64,240.9
15.27
-4,207
-
2022-11-09
SMITH PATRICK F
SOLD
-32,176.8
13.48
-2,387
PRESIDENT, INTEGRATED DRUG DEV
2022-11-01
SMITH PATRICK F
SOLD FOR TAXES
-15,214.1
12.23
-1,244
PRESIDENT, INTEGRATED DRUG DEV
2022-08-19
McLean Stephen M.
BOUGHT
326,400
16.32
20,000
-
2022-08-17
Schemick Michael Andrew
BOUGHT
416,000
16.64
25,000
CHIEF FINANCIAL OFFICER
2022-08-16
SLAINE MASON P
SOLD
-3,171,420
17.38
-182,475
-
2022-08-16
SMITH PATRICK F
SOLD
-177,100
17.71
-10,000
PRESIDENT, INTEGRATED DRUG DEV

1–10 of 50

William F. Feehery
350
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

CERT Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS    
Revenues$ 84,700$ 73,944$ 249,011$ 210,758
Cost of revenues32,81228,769100,79582,327
Operating expenses:    
Sales and marketing6,3765,08219,60813,423
Research and development6,3184,53021,60713,862
General and administrative17,32726,19953,44460,795
Intangible asset amortization10,5919,59231,09528,527
Depreciation and amortization expense4175331,3211,687
Total operating expenses41,02945,936127,075118,294
Income (loss) from operations10,859(761)21,14110,137
Other income (expenses):    
Interest expense(5,221)(3,289)(12,328)(13,549)
Other, net2,8556576,217194
Total other expenses(2,366)(2,632)(6,111)(13,355)
Income (loss) before income taxes8,493(3,393)15,030(3,218)
Provision for (benefit from) income taxes4,557(1,631)9,473349
Net income (loss)3,936(1,762)5,557(3,567)
Other comprehensive loss:    
Foreign currency translation adjustment(9,489)(2,798)(20,193)(4,041)
Change in fair value from interest rate swap, net of tax of $1,716, $(16), $2,137, $145, respectively5,279(47)6,191430
Reclassification of fair value of interest rate swap, net of tax of $0, $0, $0, $(765)   2,268
Total other comprehensive loss(4,210)(2,845)(14,002)(1,343)
Comprehensive loss$ (274)$ (4,607)$ (8,445)$ (4,910)
Net income (loss) per share attributable to common stockholders:    
Basic (in dollar per share)$ 0.03$ (0.01)$ 0.04$ (0.02)
Diluted (in dollar per share)$ 0.02$ (0.01)$ 0.03$ (0.02)
Weighted average common shares outstanding:    
Basic (in shares)157,140,166149,016,609156,523,022147,894,227
Diluted (in shares)159,587,645149,016,609159,392,534147,894,227

CERT Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 210,509$ 185,797
Accounts receivable, net of allowance for credit losses of $692 and $262, respectively74,80669,555
Restricted cash3,274827
Prepaid expenses and other current assets16,50318,548
Total current assets305,092274,727
Other assets:  
Property and equipment, net2,6092,935
Operating lease right-of-use assets11,48112,634
Goodwill696,921703,371
Intangible assets, net of accumulated amortization of $202,901 and $169,329, respectively481,536511,823
Deferred income taxes4,1584,073
Other long-term assets6,8962,167
Total assets1,508,6931,511,730
Current liabilities:  
Accounts payable3,0027,458
Accrued expenses26,55229,830
Current portion of deferred revenue40,43445,496
Current portion of long-term debt3,0203,020
Current operating lease liabilities3,4225,040
Other current liabilities1001,381
Total current liabilities76,53092,225
Long-term liabilities:  
Deferred revenue, net of current portion1,8841,531
Deferred income taxes75,52276,098
Operating lease liabilities, net of current portion8,5098,256
Long-term debt, net of current portion and debt discount290,428291,746
Other long-term liabilities1,42225
Total liabilities454,295469,881
Commitments and contingencies
Stockholders' equity:  
Preferred shares, $0.01 par value, 50,000,000 shares authorized, no shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively
Common shares, $0.01 par value, 600,000,000 shares authorized, 159,921,814 and 159,660,048 shares issued as of September 30, 2022 and December 31, 2021, respectively, 159,781,270 and 159,658,948 shares outstanding as of September 30, 2022 and December 31, 2021, respectively1,5991,596
Additional paid-in capital1,143,6381,119,821
Accumulated deficit(70,047)(75,604)
Accumulated other comprehensive loss(17,928)(3,926)
Treasury stock at cost, 140,544 and 1,100 shares at September 30, 2022 and December 31, 2021, respectively(2,864)(38)
Total stockholders' equity1,054,3981,041,849
Total liabilities and stockholders' equity$ 1,508,693$ 1,511,730